102 related articles for article (PubMed ID: 8790201)
1. Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
Fu H; Huang J; Zhao T; Wang H; Chen Y; Xu W; Pang Y; Guo W; Sun L; Wu H; Xu P; Su B; Zhang J; Chen X; Chen H
Clin Cancer Res; 2023 Dec; 29(23):4740-4750. PubMed ID: 37801296
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the Importance of Applying Various Methods of Calculation in Determining the Blood-Absorbed Dose for Patients with Differentiated Thyroid Carcinoma.
Al-Shakhrah IA
J Nucl Med Technol; 2023 Dec; 51(4):296-301. PubMed ID: 37433678
[TBL] [Abstract][Full Text] [Related]
3. Effects of Dosimetrically Guided I-131 Therapy on Hematopoiesis in Patients With Differentiated Thyroid Cancer.
Bikas A; Schneider M; Desale S; Atkins F; Mete M; Burman KD; Wartofsky L; Van Nostrand D
J Clin Endocrinol Metab; 2016 Apr; 101(4):1762-9. PubMed ID: 26900639
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary injury after radioactive iodine therapy in pediatric papillary thyroid cancer: a case report.
Halada S; Leftin Dobkin S; Baran JA; Sisko L; Robbins SL; Rapp JB; Young LR; Bauer AJ
Horm Res Paediatr; 2023 Nov; ():. PubMed ID: 37956658
[TBL] [Abstract][Full Text] [Related]
5. Genomic Considerations in the Treatment of Thyroid Carcinoma.
Hattum CJ; Elsey RJ; Meissner T; Spanos WC
JCO Oncol Pract; 2024 Apr; ():OP2400198. PubMed ID: 38621192
[TBL] [Abstract][Full Text] [Related]
6. Acute Myeloid Leukemia following Radioactive Iodine Therapy for Metastatic Follicular Carcinoma of the Thyroid.
Bishnoi K; Emerson R; Parida GK; Acharya P; Padhi S; Agrawal K
Indian J Nucl Med; 2023; 38(1):56-58. PubMed ID: 37180180
[TBL] [Abstract][Full Text] [Related]
7. Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer.
Pacilio M; Conte M; Frantellizzi V; De Feo MS; Pisani AR; Marongiu A; Nuvoli S; Rubini G; Spanu A; De Vincentis G
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885666
[TBL] [Abstract][Full Text] [Related]
8. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.
Hong CM; Shin JY; Kim BI; Song HC; Yoon JK; Won KS; Kim SM; Cho IH; Jeong SY; Lee SW; Lee J
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1661-1670. PubMed ID: 34773164
[TBL] [Abstract][Full Text] [Related]
9. I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy.
Probst S; Abikhzer G; Chaussé G; Tamilia M
Mol Imaging Radionucl Ther; 2018 Jun; 27(2):84-87. PubMed ID: 29889031
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal Side Effects of the Radioiodine Therapy for the Patients with Differentiated Thyroid Carcinoma Two Days after Prescription.
Pashnehsaz M; Takavar A; Izadyar S; Zakariaee SS; Mahmoudi M; Paydar R; Geramifar P
World J Nucl Med; 2016 Sep; 15(3):173-8. PubMed ID: 27651737
[TBL] [Abstract][Full Text] [Related]
11. Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.
Sabet A; Binse I; Dogan S; Koch A; Rosenbaum-Krumme SJ; Biersack HJ; Biermann K; Ezziddin S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):190-195. PubMed ID: 27530124
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.
Klein Hesselink EN; Links TP
Eur Thyroid J; 2015 Jun; 4(2):82-92. PubMed ID: 26279993
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine treatment of well-differentiated thyroid cancer.
Wartofsky L; Van Nostrand D
Endocrine; 2012 Dec; 42(3):506-13. PubMed ID: 22733393
[No Abstract] [Full Text] [Related]
14. Radioiodine for remnant ablation and therapy of metastatic disease.
Reiners C; Hänscheid H; Luster M; Lassmann M; Verburg FA
Nat Rev Endocrinol; 2011 Aug; 7(10):589-95. PubMed ID: 21826102
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for radioiodine therapy of differentiated thyroid cancer.
Luster M; Clarke SE; Dietlein M; Lassmann M; Lind P; Oyen WJ; Tennvall J; Bombardieri E;
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1941-59. PubMed ID: 18670773
[TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid cancer: medical management and follow-up.
Kloos RT
Curr Treat Options Oncol; 2005 Jul; 6(4):323-38. PubMed ID: 15967085
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma.
Thompson GB; Hay ID
World J Surg; 2004 Dec; 28(12):1187-98. PubMed ID: 15517490
[TBL] [Abstract][Full Text] [Related]
18. The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management.
Koch CA; Sarlis NJ
J Endocrinol Invest; 2001 Oct; 24(9):659-75. PubMed ID: 11716153
[TBL] [Abstract][Full Text] [Related]
19. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
